Flexibility to Choose From 3 FDA-Approved Dosing Regimens for Wet AMD

The recommended dose for EYLEA in Wet AMD is 2 mg administered by intravitreal injection Q4 for the first 3 months, followed by 2 mg Q8.1

Although not as effective as the recommended Q8 dosing regimen, patients may also be treated with 1 dose Q12 after 1 year of effective therapy. Patients should be assessed regularly.1

Although EYLEA may be dosed as frequently as 2 mg Q4 (≈every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed Q4 compared with Q8. Some patients may need Q4 (monthly) dosing after the first 12 weeks (3 months).1

Q4, every 4 weeks; Q8, every 8 weeks; Q12, every 12 weeks.

Only EYLEA Is Approved to Treat 4 VEGF-Driven Retinal Diseases With 1 Single-Dose–Strength PFS

The pre-filled syringe (PFS) offers a more convenient way to prepare EYLEA for administration when compared with vials1

  • Fewer components to handle
  • Helps eliminate multiple preparation steps

One dosage strength may help1

  • Simplify ordering and billing
  • Streamline inventory management

Preparation of the single-dose, pre-filled syringe for intravitreal administration

VEGF, vascular endothelial growth factor.

A demonstrated safety profile1

A library of resources for
you and your patients

Support for the reimbursement process.
Reimbursement Support

Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.

Product support for EYLEA® (aflibercept) Injection.
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

EYLEA news, events, and more.
Resources

Get the information you
and your patients need
about EYLEA.

See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. March 2021
  2. Data on file. Regeneron Pharmaceuticals, Inc.